UK Medical Device Regulations: A Shift Towards Indefinite CE Mark Recognition
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is poised to significantly alter the landscape for medical device manufacturers with a new consultation proposing the indefinite recognition of CE-marked medical devices in Great Britain. This move signals a major shift away from the post-Brexit UK Conformity Assessed (UKCA) marking regime and aims to ensure continued access to vital medical technologies.
From UKCA to CE: A Regulatory U-Turn?
Following the UK’s departure from the European Union, the MHRA introduced the UKCA mark as a standalone product safety regime for medical devices. However, recognizing the challenges and costs associated with transitioning to a new system, the government repeatedly extended transitional periods allowing CE-marked devices to remain on the Great Britain market. These extensions were initially set to expire in June 2028, with some device classes having until June 2030. Now, the MHRA is considering removing these sunset dates altogether.
Three Key Proposals Shaping the Future
The current consultation outlines three core proposals that will define the future of medical device regulation in Great Britain:
Indefinite Recognition of EU MDR and IVDR Devices
Perhaps the most significant proposal is the potential for indefinite recognition of devices compliant with the EU Medical Device Regulation (MDR) 2017/745 and the EU In Vitro Diagnostic Medical Device Regulation (IVDR) 2017/746. This would indicate that devices meeting EU standards could be placed on the Great Britain market without requiring additional assessment by a UK approved body, though registration with the MHRA would still be necessary. The MHRA is seeking feedback on whether this should apply universally or be limited to devices with equivalent or lower risk classifications under UK regulations.
Streamlined Approval for Higher-Risk Devices
If indefinite recognition is limited to devices with comparable EU and UK risk classifications, the MHRA proposes an “international reliance” route for higher-risk devices. This would involve a streamlined approval process where a UK-approved body reviews the existing EU MDR or IVDR assessments and issues an “international reliance certificate,” allowing the device to be registered and marketed in Great Britain. This approach aims to balance patient safety with the need for efficient market access.
Extension of the Transitional Period for Legacy Devices
The MHRA also proposes a six-month extension to the current transitional period for devices compliant with the older EU Medical Devices Directive 93/42/EEC (EU MDD). This would allow these devices, which currently have until December 31, 2028, to remain on the Great Britain market in line with their continued availability in the EU.
What Does This Mean for Manufacturers?
The proposed changes represent a significant win for medical device manufacturers, particularly those who have faced uncertainty and financial burdens associated with the UKCA marking transition. Indefinite recognition of CE marking would reduce the need for costly re-certification and streamline market access to Great Britain. However, manufacturers will still need to navigate the MHRA registration process.
Pro Tip: Even with potential indefinite recognition, maintaining up-to-date documentation and ensuring compliance with both EU and UK regulations is crucial for a smooth market entry.
Impact on Patient Access and Innovation
By simplifying the regulatory pathway, the MHRA hopes to ensure continued patient access to a wide range of medical devices and foster innovation in the sector. A less burdensome regulatory environment could encourage companies to launch new products in Great Britain, benefiting both healthcare providers and patients.
The Consultation Process and Next Steps
The public consultation is open until April 10, 2026, providing an opportunity for stakeholders to share their views on these proposals. The MHRA will then analyze the feedback and develop a final policy, which is expected to be announced later this year. This policy will likely shape the UK medical device regulatory landscape for years to come.
FAQ
Q: Will I still need to register my device with the MHRA?
A: Yes, even with indefinite CE mark recognition, device registration with the MHRA will still be required.
Q: What is the “international reliance” route?
A: It’s a streamlined approval pathway for higher-risk devices where a UK-approved body reviews existing EU assessments.
Q: What happens to devices certified under the EU MDD?
A: The MHRA proposes extending the transitional period for these devices until December 31, 2028.
Q: Where can I submit my feedback on the consultation?
A: Responses can be submitted here.
Did you know? The MHRA is also planning wider reforms to the UK medical device regulatory framework, expected later in 2026.
Stay informed about the evolving regulatory landscape. Explore our other articles on medical device compliance and market access strategies. Learn more.
